Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

20021,210 citationsJournal Articlebronze Open Access

Authors

Kevan C. Herold · University of California, San Francisco

William Hagopian · Pacific Northwest Diabetes Research Institute

Julie Auger · University of San Francisco

Ena Poumian-Ruiz · Columbia University

Lesley Taylor · Columbia University

David Donaldson · University of San Francisco

Stephen E. Gitelman

Abstract

Treatment with hOKT3gamma1(Ala-Ala) mitigates the deterioration in insulin production and improves metabolic control during the first year of type 1 diabetes mellitus in the majority of patients. The mechanism of action of the anti-CD3 monoclonal antibody may involve direct effects on pathogenic T cells, the induction of populations of regulatory cells, or both.

Topics & Keywords

Diabetes and associated disorders Diabetes Management and Research Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 346, Issue 22, pp. 1692-1698

DOI: 10.1056/nejmoa012864

Field-Weighted Citation Impact: 35.05